A major
challenge in myocardial infarction (MI)-related heart failure
treatment using microRNA is the efficient and sustainable delivery
of miRNAs into myocardium to achieve functional improvement through
stimulation of intrinsic myocardial restoration. In this study, we
established an in vivo delivery system using polymeric
nanoparticles to carry miRNA (miNPs) for localized delivery within
a shear-thinning injectable hydrogel. The miNPs triggered proliferation
of human embryonic stem cell-derived cardiomyocytes and endothelial
cells (hESC-CMs and hESC-ECs) and promoted angiogenesis in hypoxic
conditions, showing significantly lower cytotoxicity than Lipofectamine.
Furthermore, one injected dose of hydrogel/miNP in MI rats demonstrated
significantly improved cardiac functions: increased ejection fraction
from 45% to 64%, reduced scar size from 20% to 10%, and doubled capillary
density in the border zone compared to the control group at 4 weeks.
As such, our results indicate that this injectable hydrogel/miNP composite
can deliver miRNA to restore injured myocardium efficiently and safely.
Stem-cell-based therapies hold considerable promise for regenerative medicine. However, acute donor-cell death within several weeks after cell delivery remains a critical hurdle for clinical translation. Co-transplantation of stem cells with pro-survival factors can improve cell engraftment, but this strategy has been hampered by the typically short half-lives of the factors and by the use of Matrigel and other scaffolds that are not chemically defined. Here, we report a collagen–dendrimer biomaterial crosslinked with pro-survival peptide analogues that adheres to the extracellular matrix and slowly releases the peptides, significantly prolonging stem cell survival in mouse models of ischaemic injury. The biomaterial can serve as a generic delivery system to improve functional outcomes in cell-replacement therapy.
SummaryNon-human primates (NHPs) can serve as a human-like model to study cell therapy using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). However, whether the efficacy of NHP and human iPSC-CMs is mechanistically similar remains unknown. To examine this, RNU rats received intramyocardial injection of 1 × 107 NHP or human iPSC-CMs or the same number of respective fibroblasts or PBS control (n = 9–14/group) at 4 days after 60-min coronary artery occlusion-reperfusion. Cardiac function and left ventricular remodeling were similarly improved in both iPSC-CM-treated groups. To mimic the ischemic environment in the infarcted heart, both cultured NHP and human iPSC-CMs underwent 24-hr hypoxia in vitro. Both cells and media were collected, and similarities in transcriptomic as well as metabolomic profiles were noted between both groups. In conclusion, both NHP and human iPSC-CMs confer similar cardioprotection in a rodent myocardial infarction model through relatively similar mechanisms via promotion of cell survival, angiogenesis, and inhibition of hypertrophy and fibrosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.